Communiqués BIOSTAXPAR

Actions

BTAX

US45252A3059

Marché Fermé - OTC Markets Autres places de cotation 19:27:45 22/09/2025			Varia. 5j.	Varia. 1 janv.
0,000100 ^USD	-50,00%		-.--%	-

27/03	Callan JMB Inc. soutient la montée en puissance aux États-Unis d'une plateforme immunitaire multi-indications avec le passage en Phase 2b/3 d'une collaboration menée par DifGen Pharmaceuticals, Aveva Drug Delivery Systems, Biostax Corp et SGP Holdings	CI
25/03	DifGen Pharmaceuticals et Aveva Drug Delivery Systems nouent un partenariat stratégique avec Biostax Corp (Attune Biotech), SGP Holdings et Callan JMB	CI

Communiqués

21/02/25	Biostax Corp Announces Voluntary Delisting from OTC Pink Market and SEC Deregistration	AQ
30/11/23	Biostax Corp. to Participate in U.S. Business Action to End HIV Annual Coalition Meeting and World AIDS Day Reception	AQ
15/11/23	Biostax Announces a Director Appointment of Influential Business Leader Craig Suro	AQ
02/11/23	Biostax Announces the Appointment of Ms. Mary Clay Caperton to its Board of Directors	AQ
24/10/23	Biostax Announces FINRA Approval for Name and Ticker Symbol Change, Signals Entry into Global Substance Abuse Commercial Markets and Pioneering HIV Treatment	AQ
14/09/23	Biostax Corp Announces the Passing of Esteemed Director, H. Louis Salomonsky	AQ
29/08/23	Biostax Corp. Signs Collaboration Agreement with Immgenuity, Inc. to Pursue Remission in HIV	AQ
15/08/23	Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for the Treatment of NASH, NAFLD and AIH	AQ
30/05/23	Biostax Launches Growth Funding Round to Revitalize Affordable Healthcare	PR
20/04/23	Biostax Corp. and Statera Biopharma, Inc. reach mutually beneficial dispute settlement and amended license agreement providing clearer clinical and commercial pathways for both companies	AQ
20/04/23	IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
10/04/23	IMMUNE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
06/03/23	IMMUNE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
01/03/23	Immune Therapeutics, Inc. Announces Shareholder Approval of Name Change to Biostax Corp. and Unveils New Website, Business Strategies and Direction	AQ
03/01/23	IMMUNE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
14/11/22	IMMUNE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q)	AQ
09/11/22	IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
09/11/22	Immune Therapeutics, Inc. Announces Management Change; Moves Forward with Repositioning Strategy and Long-acting TLR4 (Toll Like Receptor 4) Antagonist JKB-122 Development	AQ
12/10/22	IMMUNE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
27/09/22	Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors	AQ
27/09/22	IMMUNE THERAPEUTICS, INC. : Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
25/08/22	Immune Announces Filing of 10-Q and Removal of Delinquency Flag on OTC Markets Stock Quotes	AQ
24/08/22	IMMUNE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION (form 10-Q)	AQ
04/08/22	Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer	AQ
04/08/22	Immune Therapeutics : Appoints Chief Financial Officer and Chief Operating Officer - Form 8-K	PU